US$6.48m (loss widened by 3.2% from FY 2023). US$0.46 loss per share (further deteriorated from US$0.44 loss in FY 2023).

This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in his ISA.

The planned registrational Phase 3 study of eRapa in FAP will be a double-blind placebo-controlled trial in 168 patients ... Biodexa's headquarters and R&D facility is in Cardiff, UK. For more ...

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potent ...

BAM has marked a significant milestone in its journey towards decarbonising its construction sites with the successful trial ...

Confirmatory Phase 3 Trial Designed to Support Commercialization of Multikine for Head and Neck Cancer Treatment. Full ...

Cenerimod is a novel oral S1P1 receptor modulator with potential to be a first- or best-in-class therapy for multiple autoimmune diseasesViatris previously acquired rights to cenerimod in all other ...

Online Music Streaming Size, Share, Trends By content type, the video segment is estimated to witness the fastest growth, registering a CAG ...

MELBOURNE, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting from March 7–11, ...

The Student Psychological Intervention Trial (SPIT) is a study consisting of two-phases. Phase 1 aims to gather information ... Similar to other recent studies in the UK and Ireland, we found very ...

Explore Kimberly-Clark’s clean energy deals and Lego’s eco-friendly tires. Discover how leaders turn sustainability ambitions ...

Elon Musk's job justification request for federal employees sparks division within Trump's administration. Follow Newsweek's live blog.